Objectives: To describe the concerns and priorities of key stakeholders in a developing country regarding ethical obligations held by researchers and perceptions of equity or “what is fair” for study participants in an HIV/AIDS clinical drug trial.
Design: Qualitative study with focus groups.
Setting: Teaching and referral hospital and rural health centre in western Kenya.
Participants: Potential HIV/AIDS clinical trial participants, clinician researchers, and administrators.
Results: Eighty nine individuals participated in a total of 11 focus groups over a four month period. The desire for continued drug therapy, most often life long, following an HIV/AIDS clinical trial was the most common priority expressed in all focus groups. Patients with and without HIV/AIDS also thought subsidisation of drug therapies and education were critical forms of compensation for clinical trial participation. Financial incentives were considered important primarily for purchasing drug therapy as well as obtaining food. Patients noted a concern for the potential mismanagement of any money offered. Clinician researchers and administrators felt strongly that researchers have a moral obligation to participants following a trial to provide continued drug therapy, adverse event monitoring, and primary care. Finally, clinician researchers and administrators stressed the need for thorough informed consent to avoid coercion of study participants.
Conclusions: Kenyan patients, clinician researchers, and administrators believe that it would be unfair to stop antiretroviral therapy following an HIV/AIDS clinical trial and that researchers have a long term obligation to participants.
- clinical trial
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
This study was funded by the Department of Medicine of the Indiana University School of Medicine and in part by grant number 1-D43-TW01082 from the Fogarty International Center, National Institutes of Health. Other than academic relationship to authors, the Department of Medicine of the Indiana University School of Medicine as the study sponsor had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. The researchers declare independence from the funders of this study.
Competing interests: the authors declare that they have no competing interests, particularly financial, with regard to participation in the focus group study, and/or preparation and submission of this manuscript for review.
Other content recommended for you
- Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
- Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015
- Supporting positive experiences and sustained participation in clinical trials: looking beyond information provision
- Cross-sectional assessment of patient attitudes towards participation in clinical trials: does making results publicly available matter?
- Conducting an ongoing HIV clinical trial during the COVID-19 pandemic in Uganda: a qualitative study of research team and participants’ experiences and lessons learnt
- Acceptability of donor funding for clinical trials in the UK: a qualitative empirical ethics study using focus groups to elicit the views of research patient public involvement group members, research ethics committee chairs and clinical researchers
- Engaging African ancestry participants in SLE clinical trials
- Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland
- Oncology patients’ experiences in experimental medicine cancer trials: a qualitative study
- Perspectives of people with inherited retinal diseases on ocular gene therapy in Australia: protocol for a national survey